金砖SBANE，Calif.，May092024（GLOBE NEWSWIRE）--Annexon，Inc。（Nasdaq:ANNX），双语harmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body，brain，and eye，today announced that Douglas Love，president and chief executive officer，will present at the Bank of America Health Care Conference on Tuesday，May142024at8:40a.m.PT。
Alive webcast of the event can be accessed under the‘Events&Presentations’section on the Investors page at www.annexonbio.com.A replay of the webcast will be archived on the Annexon website for 30days following the presentation。
About Annexon
Nasdaq:ANNX is abiopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body，brain，and eye.Annexon’s novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts，and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune，neurodegenerative and opthalmic diseases of ain-Barrésyndrome，Huntington’s disease and geographic atrophy，Annexon is rigorously advancing its mid-tolate-stage clinical trials to bring new potential treatments to patients as quickly as possible.To learn more visit annexonbio.com。
